Prime Minister congratulates Odisha for MoU between NHA and Dept of Health and Family Welfare

IMT News Desk
IMT News Desk
· 2 min read

Modi mentioned that the scheme will ensure the highest-quality healthcare at affordable rates, particularly the Nari Shakti and the elderly of Odisha

The Prime Minister, Narendra Modi has congratulated the people of Odisha on the MoU signing between the National Health Authority, Government of India, and the Department of Health and Family Welfare, Government of Odisha, for the Ayushman Bharat Pradhan Mantri Jan Arogya Yojana. Modi remarked that this scheme will ensure the highest-quality healthcare at affordable rates, particularly the Nari Shakti and the elderly of Odisha.

Replying to a post on X by Chief Minister of Odisha, Mohan Charan Majhi, the Prime Minister posted: “Congratulations to the people of Odisha! It was indeed a travesty that my sisters and brothers of Odisha were denied the benefits of Ayushman Bharat by the previous Government. This scheme will ensure the highest-quality healthcare at affordable rates. It will particularly benefit the Nari Shakti and the elderly of Odisha.”

Mohan Charan Majhi, Chief Minister, Odisha mentioned, “It is an honour for me to attend, on behalf of the people of Odisha, the MoU signing ceremony between the National Health Authority, Government of India, and the Department of Health and Family Welfare, Government of Odisha, for the Ayushman Bharat Pradhan Mantri Jan Arogya Yojana, alongside Health and Family Welfare Minister JP Nadda and other distinguished officials.”

Majhi further mentioned, “In Odisha, beneficiaries will have access to cashless treatment at over 30,000 government and private hospitals across the country. Nearly three crore individuals from 1.3 crore families are set to benefit from this initiative. Ayushman Bharat Mandirs will be established in every Panchayat of Odisha to deliver healthcare services to rural areas. An instructor will be present at each Mandir, and we will also provide additional facilities and services alongside healthcare workers. The Government of Odisha remains committed to transforming the healthcare sector through various initiatives, paving the way toward a “Viksit Odisha” by 2036 and a “Viksit Bharat” by 2047.”

PIB

Read Next

Glenmark Launches Winlevi® in Key European Markets for the Treatment of Acne Vulgaris
News
June 12, 2026

Glenmark Launches Winlevi® in Key European Markets for the Treatment of Acne Vulgaris

Glenmark Specialty S.A. (GSSA), a wholly owned subsidiary of Glenmark Pharmaceuticals Ltd., has announced the launch of Winlevi® (clascoterone 10 mg/g cream) across key markets in Europe. This follows the grant of marketing authorization of the product for the treatment of acne vulgaris in both adults and adolescents aged 12 to <18 years (with usage in […]
Article by: IMT News Desk
Thyrocare Expands Its Presence in Prayagraj with the Launch of Its New Diagnostic Laboratory
News
June 12, 2026

Thyrocare Expands Its Presence in Prayagraj with the Launch of Its New Diagnostic Laboratory

Thyrocare Technologies Limited has announced the set-up of its new diagnostic laboratory in Prayagraj, Uttar Pradesh, in association with SecondMedic. The new laboratory is equipped with advanced testing infrastructure and supported by trained professionals, enabling timely and error-free diagnostic results. It caters to both specialised and routine testing requirements, offering support to ongoing and preventive […]
Article by: IMT News Desk
AstraZeneca Gets CDSCO Approval for Trastuzumab Deruxtecan in HER2-Positive Breast Cancer
News
June 12, 2026

AstraZeneca Gets CDSCO Approval for Trastuzumab Deruxtecan in HER2-Positive Breast Cancer

AstraZeneca Pharma India Ltd. (AZPIL) announced that the Central Drugs Standard Control Organisation (CDSCO) has approved an additional indication for Trastuzumab Deruxtecan 100 mg/5 mL vial lyophilized powder for concentrate for solution for infusion, in combination with Pertuzumab as a first-line treatment for adult patients with unresectable or metastatic HER2-positive (IHC 3+ or ISH+) breast cancer. In India, HER2-positive breast […]
Article by: IMT News Desk
Alembic Pharmaceuticals Limited announces USFDA Tentative Approval for Larotrectinib Capsules
News
June 11, 2026

Alembic Pharmaceuticals Limited announces USFDA Tentative Approval for Larotrectinib Capsules

Alembic Pharmaceuticals Limited (Alembic) announced that it has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Larotrectinib Capsules, 25 mg and 100 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Vitrakvi Capsules, 25 mg and 100 mg, of […]
Article by: IMT News Desk